Latest Corcept Therapeutics Stories
Feature spotlights both drug companies' digital marketing initiatives for getting their name out to patient and physician community; winning companies to be honored at CBI's iPharma 2014 summit
Winners include Teva's Coxapone, a specialty drug for the treatment of chronic disease, and Corcepts' KORLYM, an orphan drug for a rare condition NEW YORK, May 7, 2014 /PRNewswire/
US-based pharmaceutical company Corcept Therapeutics has announced that Eli Lilly and Company has agreed to fund studies to test the effectiveness of Corcept's selective GRII receptor antagonist, CORT 108297, in rat models of olanzapine induced weight gain.
- The act of sweetening by admixture of some saccharine substance.